Skip to main content
. 2018 Aug 1;315(4):R840–R847. doi: 10.1152/ajpregu.00440.2017

Fig. 1.

Fig. 1.

A: timeline of selected key events in lysine-specific demethylase (LSD1) research and development in therapeutically targeting LSD1 inhibitors in sickle cell disease (SCD). B: the LSD1 inhibitor RN-1 has 2 distinct mechanisms. One addresses sickle hemoglobin (HbS) polymerization-mediated sickling, and the other addresses red blood cell (RBC) reactive oxygen species (ROS) generation-induced hemolysis. HbF, fetal hemoglobin; Retics, reticulocytes.